Related Experiment Videos
[Experimental and clinical studies of an ampicillin suppository (KS-R1) in pediatrics]
Insights
Ampicillin (ABPC) suppositories (KS-R1) show good absorption and effectiveness against respiratory infections. This study found KS-R1 to be a useful alternative to oral ampicillin for treating susceptible bacterial infections.
Area of Science:
- Pharmacology
- Microbiology
Context:
- Pediatric infections often require effective antibiotic treatment.
- Ampicillin is a common antibiotic for bacterial infections.
- Alternative drug delivery methods are sought to improve patient compliance and efficacy.
Purpose:
- To evaluate the pharmacokinetic profile and clinical efficacy of ampicillin suppositories (KS-R1).
- To assess the effectiveness of KS-R1 against common respiratory pathogens.
- To compare KS-R1 with oral ampicillin for treating bacterial infections.
Summary:
- Ampicillin suppositories (KS-R1) demonstrated good absorption, reaching peak levels within 15 minutes and maintaining high concentrations for one hour.
- A dosage of 20-40 mg/kg/day effectively treated acute respiratory tract infections in 94% of 35 cases over 3-5 days.
- KS-R1 eradicated key pathogens including Group A Streptococcus, S. pneumoniae, and H. influenzae, with minimal side effects like mild diarrhea observed in some patients.
Impact:
- KS-R1 offers a viable alternative to oral ampicillin, particularly for pediatric patients or those with difficulty swallowing oral medications.
- The study supports the use of ampicillin suppositories for treating infections caused by ampicillin-susceptible organisms.
- Effective treatment of respiratory infections with KS-R1 contributes to improved patient outcomes and reduced antibiotic resistance.
Abstract:
Absorption of ampicillin (ABPC) suppository (KS-R1) was good with the peak level of ABPC at 15 minutes and the continuous high level for 1 hour by the administration of about 10 approximately 18 mg/kg. About 40% of active form of administered ABPC was excreted into urine within 6 hours. KS-R1 at the dose of about 20-40 mg/kg/day divided into 3-4 times was very against acute respiratory tract infection by the treatment for 3-5 days. The effective rate was 94% in 35 cases. By the administration of KS-R1, group A Streptococcus, S. pneumoniae and H. influenzae were eradicated. After the insertion of KS-R1, weak diarrhea and the discharge of KS-R1 were observed in 2 cases and 3 cases, respectively. It was concluded that KS-R1 is very useful drug for the treatment of infections by ABPC sensitive organisms in place of the oral form of ABPC.